Despite these effects, the real benefit of these drugs in PD is not well known.4There is evidence that people with type-2 diabetes have an increased risk of developing PD, although the precise role of antidiabetic medications, such as GLP-1 agonists, on PD risk lacks further elucidation.5To date, the efficacy and safety of GLP-1 analogs for PD treatment remain unanswered questions. Here, GLP1R is linked to Parkinson disease.